AstraZeneca's oral relaxin drug AZD5462 hits its HFpEF endpoint but narrowly misses in HFrEF in the Phase 2b LUMINARA heart failure trial.
MUNICH — AstraZeneca’s oral relaxin agonist was able to improve cardiac function in some, though not all, patients in a mid-stage trial. While the study was …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
New data could widen use of AstraZeneca, Amgen immune disease drug
A Novartis drug cut inflammation. Can it improve heart outcomes?
AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease - Amgen (NASDAQ:AMGN), AstraZenec
AstraZeneca shares sink up to 9% after Wainua misses cardiovascular endpoint in Phase 3 ATTR-CM trial with partner Ionis.
AstraZeneca detailed the surprise failure of a closely watched heart disease trial, a study with ripple effects for a competitive…
AstraZeneca posts Q2 pipeline setbacks: mixed ADC data in gastric cancer, an Ultomiris TMA trial miss and an Imfinzi liver cancer…
AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive…
AstraZeneca advances oral GLP-1 elecoglipron to Phase 3 following strong weight loss & diabetes data at ADA 2026. Get the trial…
After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI)…
